Regeneus Ltd. (AU:CMB) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cambium Bio Limited has successfully raised A$3.0 million in a capital round involving strategic and existing investors, including AventaCell Biomedical Corp and Zheng Yang Biomedical Technology. This funding will support the advancement of Cambium’s lead product, Elate Ocular®, into Phase 3 clinical trials for dry eye disease. The investment also highlights strong confidence in Cambium’s innovative biologics and its growth potential in the regenerative medicine field.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.